Sells vitamins, minerals and supplements in India under brands like Neurobion (B-vitamin / nerve care), Evion (Vitamin E / muscle health), Livogen (iron), and Polybion, distributed mainly through pharmacies and increasingly through e-pharmacy platforms. The portfolio is concentrated in nerve care, muscle health and iron deficiency, with recent launches in gummy and cream formats such as Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream. Distribution runs on a super-distributor go-to-market model that has expanded Neurobion's pharmacy reach by 1.4x in five years, adding roughly 100,000 new stores. Exports contributed ₹50 crore (+12% YoY) with the Sri Lanka business growing 30%+. The business is asset-light (capex 1.1% of revenue), with materials being the largest cost at 21.8% of revenue, followed by employee costs at 15.8% and other operating expenses at 25.8%, and it generated operating cash flow of ₹338 crore in FY26. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Nerve care / B-vitamin portfolio, Vitamin E / muscle health, Iron supplements, Polybion / B-complex range, Exports. Brand-led, asset-light vitamins and supplements company with high margins and low capital intensity
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 819 | 928 | 867 | 934 | 1,408 |
| EBITDA (ex other income) | 209 | 279 | 258 | 318 | 457 |
| margin % | 25.5 | 30.0 | 29.7 | 34.1 | 32.4 |
| Owners' profit | 151 | 200 | 184 | 234 | 327 |
| EPS, as reported (₹) | 91.20 | 120.30 | 111.00 | 141.22 | 196.94 |
| ROE % · ROCE % | — · — | — · — | — · — | 43.7 · 53.9 | 62.3 · 76.8 |
| Debt / equity (x) | — | — | — | 0.00 | 0.00 |
| Cash from operations | — | — | — | 169 | 338 |
| Capex | — | — | — | 0 | (16) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 313 | 310 | 311 | 339 | 325 | 374 | 370 | 364 |
| Profit before tax | 111 | 122 | 79 | 89 | 119 | 109 | 133 | 129 |
| Net profit | 82 | 91 | 61 | 66 | 89 | 78 | 95 | 96 |
| EPS (₹) | 49.60 | 54.76 | 36.86 | 39.87 | 53.34 | 46.74 | 56.99 | 57.92 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 4 Sept 2026 · Re-appointment of Mr. S. Madhavan as Independent Director approved | management changes | medium | — | — |
| 4 Sept 2026 · P and G Health 59th AGM: All 5 Resolutions Approved with Over 99% Support | board shareholder meetings | low | — | — |
| 3 Sept 2026 · P&G Health 59th AGM held; FY26 sales up 16%, PAT up 30% | board shareholder meetings | medium | — | — |
| 12 Aug 2026 · 59th AGM scheduled on September 3, 2026 at 2:30 PM | board shareholder meetings | low | — | — |
| 12 Aug 2026 · BRSR Report for FY ended March 31, 2026 filed with stock exchanges | compliance | low | — | — |
| 12 Aug 2026 · P&G Health FY26 Annual Report filed; 59th AGM on September 3, 2026 | board shareholder meetings | medium | — | — |
| 12 Aug 2026 · P&G Health 59th AGM on Sep 3, 2026; FY26 PAT up 30% to Rs 327 cr | board shareholder meetings | low | — | — |
| 10 Aug 2026 · Revised AGM date and record date for final dividend | corporate actions | medium | — | — |
| 6 Aug 2026 · P&G Health Q1 FY27: Sales up 7% to 356 cr, PAT up 45% to 96 cr | compliance | low | — | — |
| 6 Aug 2026 · P&G Health Q1 FY27: profit jumps 26 percent on property sale gain | results | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 12.4 |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 25.1 | 28.9 | 73 of 169 | 57% |
| P/B | 17.1 | 3.3 | 156 of 163 | 4% |
| ROCE | 76.7 | 10.8 | 2 of 183 | 100% |
| ROE | 62.3 | 10.4 | 4 of 171 | 98% |
| Debt / Equity | 0.0 | 0.1 | 6 of 171 | 77% |
| EBITDA margin | 37.2 | 17.5 | 14 of 165 | 92% |
| Revenue growth | 7.4 | 16.3 | 104 of 161 | 36% |
| Profit growth | 45.3 | 30.9 | 67 of 158 | 58% |
| Market cap | 8964 | 839 | 46 of 182 | 75% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
